WHAT THE STUDY ACTUALLY SAYS

Oral semaglutide cut total heart events, not just first ones, in a diabetes trial

A prespecified analysis of the 9,650-patient SOUL trial counted recurrent as well as first cardiovascular events. Oral semaglutide lowered the total burden by about 14% against placebo.

Total first and subsequent 3-point MACE events over the trialOral semaglutide: 683; Placebo: 7910400800Oral semaglutide683Placebo791
Total first and subsequent 3-point MACE events over the trial
GroupValue (value)
Oral semaglutide683
Placebo791
Total first and subsequent 3-point MACE events over the trial Count of all major cardiovascular events, first and recurrent, in each 1:1-randomised group [s1]. Source: JAMA Cardiology

Most cardiovascular trials count only a patient's first major event — the first heart attack, stroke or cardiovascular death — and then, for the primary analysis, stop the clock. But patients who survive a first event remain at risk of more, and a treatment's full value includes the events it prevents second and third time round. A prespecified secondary analysis of the SOUL trial, published in JAMA Cardiology, applies that fuller accounting to oral semaglutide — and finds the benefit holds up [s1].

What the analysis did

SOUL was a double-blind, placebo-controlled, event-driven phase 3b trial conducted from June 2019 to September 2024, with a median follow-up of 49.5 months (interquartile range 44.0 to 54.9), across 444 centres in 33 countries [s1]. It enrolled people with type 2 diabetes who also had atherosclerotic cardiovascular disease, chronic kidney disease, or both [s1]. Participants were randomly assigned 1:1 to once-daily oral semaglutide, at a maximal dose of 14 mg, or to placebo, each added to standard care [s1]. The trial is registered as NCT03914326 [s2].

The original trial reported that oral semaglutide reduced the risk of a first three-point major adverse cardiovascular event — the composite of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death [s1]. This new analysis asked a different question: what is the effect on total events, first plus subsequent, which is a measure of the overall burden of disease rather than the timing of a first hit [s1]. In all, 9,650 participants were randomised; their median age was 66.0 years and 6,860 (71.1%) were male [s1].

What it found

Counting all events, there were fewer in the oral-semaglutide group: 683 total three-point MACE (579 first and 104 subsequent events) versus 791 in the placebo group (668 first and 123 subsequent) [s1]. The mean ratio was 0.86 (95% confidence interval 0.76 to 0.97; P=0.01) — roughly a 14% lower total event rate [s1].

A broader composite that added death from non-cardiovascular causes pointed the same way: 910 total events with oral semaglutide against 1,048 with placebo, 138 fewer, for a mean ratio of 0.87 (95% CI 0.79 to 0.95; P=0.004) [s1]. As previously reported, adverse events led to treatment discontinuation in 749 participants (15.5%) on oral semaglutide and 559 (11.6%) on placebo [s1].

How to read it

The value of a total-event analysis is that it reflects what a treatment does to the whole course of disease, not just to the first milestone — and here it reinforces, rather than revises, the trial's main conclusion [s1]. The direction and rough size of the benefit are consistent with the original first-event result, which is the reassuring pattern: the headline finding was not an artefact of where the clock stopped.

The caveats are the ordinary ones for an analysis of this kind. This is a secondary analysis, prespecified but still downstream of the trial's primary question, so it is best read as corroboration rather than a fresh, independent result [s1]. The subsequent-event counts are modest — 104 and 123 — so the total-event result is driven largely by first events, and the extra precision from counting recurrences is limited [s1]. The population was specifically high-risk — type 2 diabetes plus established cardiovascular or kidney disease — so the findings speak to that group, not to lower-risk patients [s1]. And the higher discontinuation rate on the drug is a reminder that tolerability shapes who stays on treatment long enough to benefit [s1].

What to watch

The questions that follow are whether total-event analyses like this one begin to feature in how regulators and guideline committees describe a drug's cardiovascular benefit, and how oral semaglutide's effect compares with the injectable version and with other agents in the same high-risk diabetic population. For now, the finding is narrow and solid: across the full count of events, oral semaglutide lowered the total burden of major cardiovascular events by about 14% against placebo in high-risk type 2 diabetes [s1].

This article describes clinical-trial results and is not medical advice. Decisions about diabetes and cardiovascular treatment should be made with a clinician.

Sources

  1. First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial — JAMA Cardiology , November 11, 2026
  2. A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL) (NCT03914326) — ClinicalTrials.gov

More on

Related coverage